FacebookTwitterGoogle+RedditEmail

It’s the Cymbalta Stupid

by MARTHA ROSENBERG

Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to “educate” doctors about the pain-and-fatigue ailment fibromyalgia–more than it spent for diabetes and Alzheimer’s which people already know they have.

But finding new diseases to justify a drug’s existence is the normal way pharma operates.

Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month–$615 million for criminally promoting it for dementia–another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into “rebates” at the same time. (And how was your year?)

And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis.

But Lilly’s fibromyalgia-fighting drug, Cymbalta (duloxetine)–its second best seller after Zyprexa–is anything but normal.

Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004–who hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems–it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides and suicide attempts.

A 37-year-old man described in the Feb. 2008 Journal of Clinical Psychopharmacology with a stable marriage and employment and no history of mental problems tried to kill himself with carbon monoxide two months after taking Cymbalta for back pain. “The patient was unable to state exactly why he wanted to commit suicide,” write the four physician authors all with the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center who note he returned to normal when the drug was stopped.

A 63-year-old man with no history of suicide attempts or ideation was similarly “unable to explain why he was having thoughts of wanting to die,” say the authors after becoming suicidal two weeks after being put on Cymbalta for fatigue, insomnia and sadness.

Last January, a Texas man prescribed Cymbalta for peripheral neuropathy because of a job that required him to be on his feet all day with no history mental problems “had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself,” his family wrote a reporter.

In Feb. 2007, a 19-year-old Wisconsin college student recently put on Cymbalta “checked out books for a paper he was to write over the weekend,” emailed his resume “to see if he could get a spot on Obama’s team for the summer” and “then hung himself from his loft bed in his dorm,” writes his family. One month earlier, a 21-year old Midwest college student, recently put on Cymbalta, took his own life three minutes after speaking to his family while driving home and sounding fine, the family wrote a reporter.

Nor are incomprehensible and abrupt suicide attempts on Cymbalta a US phenomenon.

Doctors Bilal Salem and Elie Karam of the Saint George Hospital University Medical Center in Beirut, Lebanon write of similar “suicidality in apparently nonsuicidal patients after starting or increasing Duloxetine,” in the June 2008 Clinical Practice and Epidemiology in Mental Health.

Approved as an antidepressant and for diabetic nerve pain in 2004–soon after the Johnson suicide thanks to an unfazed FDA–Cymbalta soon proved to be the “Swiss Army Knife” of Lilly drugs says its hometown paper the Indianapolis Star–approved for general anxiety disorder and maintenance treatment of depression in 2007, for fibromyalgia in 2008 and with approvals for chronic knee and low back pain expected shortly.

In Europe it is in use for stress urinary incontinence but in the US its side effect of urinary retention landed Cymbalta on the FDA’s first Potential Signals of Serious Risks danger list in 2008. (FDA won’t release suicidal rates from stress urinary incontinence trials says reporter Jeanne Lenzer on Slate, who estimates them as 400 per 100,000 person-years for middle aged women.)

But some, like Shannon Brownlee, author of “Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer,” question the revenue-driven prescribothan. Should drugs “that may have a really serious side effect called suicide,” be used for simple knee or back pain, she asks in the Star.

No kidding! Cymbalta is also being studied for binge eating, social phobia, chronic fatigue, restless legs disorder, seasonal affective disorder, migraines, attention deficit disorder and childhood depression–despite known pediatric risks–PMS, menopause, alcoholism, panic disorder, obsessive compulsive disorder, kleptomania and the important medical condition: tennis elbow.

At the American Academy of Pain Medicine Annual Meeting in January, Lilly presented a study by its own doctors finding Cymbalta was superior to placebo in knee pain–in keeping with its penchant to publish studies by Lilly funded and Lilly employed doctors saying Cymbalta is safe.

Cymbalta is also a good use of state and third party payer dollars say Lilly funded doctors in “Differences In Medication Adherence and Healthcare Resource Utilization Patterns: Older Versus Newer Antidepressant Agents In Patients With Depression And/Or Anxiety Disorders” in the 2008-22 CNS Drugs who are fighting the “restrictive reimbursement policies for newer antidepressants,” in which pharmacy benefits managers are saying you want us to spend WHAT?

Getting benefits managers to cover the $200 a month cost for Cymbalta prescriptions for fibromyaglia may also be tough since the ailment has no clear cause, blood test or cure. Maybe Lilly will offer pointers in the medical courses it is funding.

MARTHA ROSENBERG is a columnist/cartoonist who writes about public health. She can be reached at: mrosenberg@evmark.org

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:
Weekend Edition
July 29, 2016
Friday - Sunday
Michael Hudson
Obama Said Hillary will Continue His Legacy and Indeed She Will!
Jeffrey St. Clair
She Stoops to Conquer: Notes From the Democratic Convention
Rob Urie
Long Live the Queen of Chaos
Ismael Hossein-Zadeh
Evolution of Capitalism, Escalation of Imperialism
Margot Kidder
My Fellow Americans: We Are Fools
Lewis Evans
Executing Children Won’t Save the Tiger or the Rhino
Vijay Prashad
The Iraq War: a Story of Deceit
Chris Odinet
It Wasn’t Just the Baton Rouge Police Who Killed Alton Sterling
Brian Cloughley
Could Trump be Good for Peace?
Patrick Timmons
Racism, Freedom of Expression and the Prohibition of Guns at Universities in Texas
Gary Leupp
The Coming Crisis in U.S.-Turkey Relations
Pepe Escobar
Is War Inevitable in the South China Sea?
Norman Pollack
Clinton Incorruptible: An Ideological Contrivance
Robert Fantina
The Time for Third Parties is Now!
Andre Vltchek
Like Trump, Hitler Also Liked His “Small People”
Serge Halimi
Provoking Russia
David Rovics
The Republicans and Democrats Have Now Switched Places
Andrew Stewart
Countering The Nader Baiter Mythology
Rev. William Alberts
“Law and Order:” Code words for White Lives Matter Most
Ron Jacobs
Something Besides Politics for Summer’s End
David Swanson
It’s Not the Economy, Stupid
Erwan Castel
A Faith that Lifts Barricades: The Ukraine Government Bows and the Ultra-Nationalists are Furious
Steve Horn
Did Industry Ties Lead Democratic Party Platform Committee to Nix Fracking Ban?
Robert Fisk
How to Understand the Beheading of a French Priest
Colin Todhunter
Sugar-Coated Lies: How The Food Lobby Destroys Health In The EU
Franklin Lamb
“Don’t Cry For Us Syria … The Truth is We Shall Never Leave You!”
Caoimhghin Ó Croidheáin
The Artistic Representation of War and Peace, Politics and the Global Crisis
Frederick B. Hudson
Well Fed, Bill?
Harvey Wasserman
NY Times Pushes Nukes While Claiming Renewables Fail to Fight Climate Change
Elliot Sperber
Pseudo-Democracy, Reparations, and Actual Democracy
Uri Avnery
The Orange Man: Trump and the Middle East
Marjorie Cohn
The Content of Trump’s Character
Missy Comley Beattie
Pick Your Poison
Kathleen Wallace
Feel the About Turn
Joseph Grosso
Serving The Grid: Urban Planning in New York
John Repp
Real Cooperation with Nations Is the Best Survival Tactic
Binoy Kampmark
The Scourge of Youth Detention: The Northern Territory, Torture, and Australia’s Detention Disease
Kim Nicolini
Rain the Color Blue with a Little Red In It
Cesar Chelala
Gang Violence Rages Across Central America
Phillip Kim et al.
Open Letter to Bernie Sanders from Former Campaign Staffers
Tom H. Hastings
Africa/America
Robert Koehler
Slavery, War and Presidential Politics
Charles R. Larson
Review: B. George’s “The Death of Rex Ndongo”
July 28, 2016
Paul Street
Politician Speak at the DNC
Jeffrey St. Clair
Night of the Hollow Men: Notes From the Democratic Convention
FacebookTwitterGoogle+RedditEmail